Equities researchers at StockNews.com assumed coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a research report issued on Wednesday. The brokerage set a "hold" rating on the stock.
NantHealth Trading Down 0.6 %
Shares of NASDAQ NH opened at $3.13 on Wednesday. NantHealth has a twelve month low of $1.57 and a twelve month high of $15.75. The stock has a fifty day simple moving average of $2.41 and a 200-day simple moving average of $1.11. The stock has a market capitalization of $24.13 million, a PE ratio of -0.41 and a beta of 1.96.
Get
NantHealth alerts:
NantHealth (NASDAQ:NH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter. The firm had revenue of $16.63 million during the quarter.
Institutional Investors Weigh In On NantHealth
A number of institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in shares of NantHealth during the 2nd quarter worth $36,000. Millennium Management LLC purchased a new position in shares of NantHealth in the 2nd quarter worth $110,000. Atria Wealth Solutions Inc. raised its position in shares of NantHealth by 117.7% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company's stock worth $205,000 after buying an additional 265,949 shares during the period. Finally, Hartline Investment Corp purchased a new position in shares of NantHealth in the 2nd quarter worth $65,000. Institutional investors and hedge funds own 4.50% of the company's stock.
NantHealth Company Profile
(Get Rating)
NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.
Read More
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com的股票研究人员假设了NantHealth(纳斯达克：NH-GET评级)在周三发布的一份研究报告中。该经纪公司对该股设定了“持有”评级。
NantHealth股价下跌0.6%
周三，纳斯达克NH的股价开盘报3.13美元。NantHealth的12个月低点为1.57美元，12个月高位为15.75美元。该股的50日简单移动均线为2.41美元，200日简单移动均线为1.11美元。该股市值为2,413万美元，市盈率为-0.41，贝塔系数为1.96。
到达
NantHealth警报：
NantHealth(纳斯达克：NH-GET评级)最近一次发布季度收益数据是在11月3日星期四。该公司公布了该季度每股收益(EPS)(0.13美元)。该公司本季度的收入为1663万美元。
机构投资者看好NantHealth
一些机构投资者和对冲基金最近调整了对该公司的持股。高盛股份有限公司在第二季度购买了价值36,000美元的南洋健康新股头寸。Millennium Management LLC在第二季度购买了价值11万美元的NantHealth新股头寸。Atria Wealth Solutions Inc.在第二季度将其在NantHealth的股票头寸提高了117.7%。Atria Wealth Solutions Inc.在此期间又购买了265,949股Atria Wealth Solutions Inc.，目前持有491,942股该公司股票，价值20.5万美元。最后，Hartline Investment Corp在第二季度购买了价值6.5万美元的NantHealth股票的新头寸。机构投资者和对冲基金持有该公司4.50%的股票。
NantHealth公司简介
(获取评级)
NantHealth，Inc.是一家以证据为基础的个性化保健公司，致力于为癌症等危重疾病提供治疗。该公司支持治疗决策，改善患者结局，验证治疗选项，实现高质量护理，降低成本，确保适当的报销，并简化实施和部署。
阅读更多内容
- 免费获取StockNews.com关于NantHealth(NH)的研究报告
- Verizon，Charge在过去的一个月里趋势更高：他们现在购买吗？
- 股利之王Sysco：逢低买入
- 天才集团股票1600%的涨幅合理吗？
- 在进一步审查后，投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖出另一个收购机会吗？
接受《NantHealth Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对NantHealth和相关公司的最新新闻和分析师评级的每日简要摘要。
